Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Lomustine in First Recurrence of Glioblastoma
NCT01290939Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2011
- Primary completion
- Oct 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in glioblastoma multiforme (GBM), sponsored by European Organisation for Research and Treatment of Cancer. Started Oct 2011; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT01290939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01290939.